Inhibition of IDE were suggested in the literature to be beneficial to both type I and type II diabetic. Nevertheless, currently there is no specific IDE inhibitor beside insulin itself or targeting Zink in the core of the enzymatic activity that might affect other enzymes. Recently, IDE has been proposed as the receptor for varicella-zoster virus (VZV). Based on this we have developed short peptides library of 8-20 amino acid peptide that can specifically inhibit IDE activity.We showed that IDE inhibitor can ameliorate diabetes symptoms both in type 1 and type 2 diabete mouse models and can increase blood insulin insulin growth facor levels. Furthermore, our preliminary results show that treatment with nasal IDE inhibitor significantly improve cognitive behavior in AD mouse model and dompaninergic neuronal cells in vitro. We expect that the IDE inhibitor will increase neuronal survival and activity leading to novel therapeutic strategy in neurodegenrative diseases such as AD and PD
Project ID : 10-2014-819
Inhibition of IDE were suggested in the literature to be beneficialto both type I and type II diabetic. Nevertheless, currently there is no specific IDE inhibitor beside insulin itself or targeting Zink in the core of the enzymatic activity that might affect other enzymes. Recently, IDE has been proposed as the receptor for varicella-zoster virus (VZV). Based on this we have developed short peptides library of 8-20 amino acid peptide that can specifically inhibit IDE activity.
We showed that IDE inhibitor can ameliorate diabetes symptoms both in type 1 and type 2 diabetes mouse models and can increase blood insulin growth factor levels. Furthermore, our preliminary results show that treatment with nasal IDE inhibitor significantly improve cognitive behavior in AD mouse model and dopaminergic neuronal cells in vitro. We expect that the IDE inhibitor will increase neuronal survival and activity leading to novel therapeutic strategy in neurodegenerative diseases such as AD and PD
Project manager
Elisha Natan
Director BD
Project researchers
Dan Frenkel
T.A.U Tel Aviv University, Life Sciences
Neurobiology
Daniel Offen
T.A.U Tel Aviv University, Medicine-Sackler Faculty
Felsenstein Medical Res Center-Beilinson
Uri Ashery
T.A.U Tel Aviv University, Life Sciences
Neurobiology
Ramot is Tel Aviv University's (TAU) technology transfer company and its liaison to industry, bringing promising scientific discoveries made at the university to industry's attention. The company provides the legal and commercial frameworks for inventions made by TAU faculty, students and researchers, protecting discoveries with patents and working jointly with industry to bring scientific innovations to the market.
Create your free account to connect with RAMOT at Tel Aviv University Ltd. and thousands of other innovative organizations and professionals worldwide
Send a request for information
to RAMOT at Tel Aviv University Ltd.
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
